Plasma metabolic signatures uncover therapeutic response and prognosis of third-generation EGFR-TKI treatment in patients with NSCLC-the WES data
| Title | Plasma metabolic signatures uncover therapeutic response and prognosis of third-generation EGFR-TKI treatment in patients with NSCLC-the WES data |
|---|---|
| Description | Advanced EGFR T790M-mutated non-small cell lung cancer (NSCLC) inevitably develops resistance to third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) therapy. Metabolic reprogramming support EGFR-TKI resistance, while thorough metabolomics clinical studies are limited. Here, we enrolled 186 NSCLC patients from Phase I and IIa clinical studies and characterized responsive metabolic features of third-generation EGFR-TKI. Our study included locally advanced or metastatic NSCLC patients from the open-label, single-arm, phase I/IIa study of BPI-7711(NCT03386955). Tumor diagnosis was confirmed by histology or cytology, with EGFR-sensitive mutations (including Exon19Deletion, L858R, G719X, L861QandS768I). Two hundred and twenty plasma samples of 186 patients were collected in 16 hospitals (220 for metabolism,49 for WES and 14 for proteomics). |
| Organism | Homo sapiens |
| Data Type | Other Type of Genomic Data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA018003 |
| Release Date | 2024-07-01 |
| Submitter | Yuankai Shi (syuankaipumc@126.com) |
| Organization | National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences |
| Submission Date | 2023-06-29 |
The data cannot be downloaded as it has not yet been registered in the Human Genetic Resource Management Platform of MOST.
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX004445-01 | The mutation data of 49 patients | 1 | Other Type of Genomic Data | 42.8 MB | maf | 0 | Unavailable |